"Isomorphic Labs is focused on creating a general drug design engine that applies AI across various disease areas, not just specific targets or modalities."
"Isomorphic Labs, a London-based drug developer, aims to utilize AI in breakthrough drug discovery and ultimately strives to 'solve all diseases'."
Isomorphic Labs, a subsidiary of Alphabet Inc., is preparing to initiate human clinical trials for AI-developed drugs using technology from DeepMind's AlphaFold3. Founded in 2021, the company aims to leverage AI to create a general drug design engine applicable across various diseases. With the ambition to eventually address all diseases, Isomorphic Labs represents a growing trend of tech companies integrating AI into healthcare and medicine. Early advancements include improved diagnostics tools capable of outperforming human physicians in accuracy.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]